Health

Evkeeza (evinacumab-dgnb) Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

DailyTrendDailyTrend
Sep 30, 2025 - 02:00
 0  0
TARRYTOWN, N.Y., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Kennedy Says U.S. Rejects Global Health Goals

Kennedy Says U.S. Rejects Global Health Goals

DailyTrend Sep 25, 2025  0  0

Update on Alert: Infusion Set Performance Issue from BD

Update on Alert: Infusion Set Performance Issue from BD

DailyTrend Sep 30, 2025  0  0

What is a Medical Device Recall?

What is a Medical Device Recall?

DailyTrend Sep 30, 2025  0  0

Trump’s Pharma Tariffs Spare Richest Drugmakers

Trump’s Pharma Tariffs Spare Richest Drugmakers

DailyTrend Sep 26, 2025  0  0

Medical Groups Warn Against Visa Fees for Foreign Doctors

Medical Groups Warn Against Visa Fees for Foreign Doctors

DailyTrend Sep 26, 2025  0  0

Blood and Plasma Warming Device Correction: 3M Company Issues Correction for Ranger Blood/Fluid Warming System

Blood and Plasma Warming Device Correction: 3M Company ...

DailyTrend Sep 24, 2025  0  0